Quantcast

Latest Dendreon Stories

2011-01-21 08:30:00

VANCOUVER, Canada, Jan. 21, 2011 /PRNewswire-Asia/ -- Insiderslab.com issues new research reports that highlight large insider trades found in for Oracle, Hewlett-Packard, State Street, Walt Disney, Aruba, & Dendreon. Read our research reports with Interactive Insider Trading Charts and Insider Trade Statistics below. Insider data is not only useful in helping potential buyers, but also maybe invaluable to investors looking at for stocks they already own. Inserslab.com is attentive...

2011-01-14 10:13:00

SEATTLE, Jan. 14, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the pricing of a public offering of $540 million aggregate principal amount of 2.875% convertible senior notes due January 15, 2016 (the "Notes") in an offering registered under the Securities Act of 1933, as amended (the "Securities Act"), which was upsized from its previously announced $500 million offering. The Notes will be convertible into cash, shares of Dendreon's common stock (the "Common...

2011-01-13 15:10:00

SEATTLE, Jan. 13, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due January 15, 2016 (the "Notes") in an offering registered under the Securities Act of 1933, as amended (the "Securities Act"). The Notes will be convertible into cash, shares of Dendreon's common stock (the "Common Stock") or a combination of cash and shares of...

2011-01-07 07:30:00

SEATTLE, Jan. 7, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced several updates regarding the U.S. commercialization of PROVENGE® (sipuleucel-T), the European strategy for PROVENGE, and progress on its pipeline. The Company will host a conference call at 9:00 a.m. ET to review additional details. "Last year was foundational for Dendreon with the successful introduction of PROVENGE as the world's first autologous cellular immunotherapy," said...

2011-01-06 15:00:00

SEATTLE, Jan. 6, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) management will host a conference call on Friday, January 7, 2011 at 9:00 a.m. ET to provide updates on U.S. commercialization progress, European strategy for PROVENGE, and pipeline progress. Date: Friday, January 7, 2011 Time: 9:00 a.m. ET / 6:00 a.m. PT Dial-in: 1-877-548-9590 (domestic) or +1-720-545-0037 (international); conference pass code 35063654 Webcast:...

2011-01-06 12:38:00

SAN FRANCISCO, Jan. 6, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Opexa Therapeutics, Inc. (Nasdaq: OPXA) and raised its twelve month target price from $4.40 to $6.50. Ross Silver, Principal Analyst at Vista Partners stated, "Opexa announced yesterday that their lead clinical candidate Tovaxin®, an autologous cellular immunotherapy for the treatment of Multiple sclerosis, is now positioned from a regulatory perspective to advance...

2011-01-05 06:30:00

SEATTLE, Jan. 5, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2011 at 11:30 a.m. PT. The presentation will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor...

2010-12-15 15:02:39

The promise of vaccines targeted against various types of cancer has raised the hopes of patients and their families. The reality, however, is that these promising treatments are difficult to develop. One of the challenges is identifying a discrete cellular target to stop cancer growth without inactivating the immune system. Scientists at UNC Lineberger Comprehensive Cancer Center report a laboratory finding that has the potential to increase the effectiveness of therapeutic cancer vaccines....

2010-12-08 06:30:00

SEATTLE, Dec. 8, 2010 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the 2010 Deutsche Bank BioFEST conference in Boston on December 15, 2010 at 10:30 a.m. ET. The presentation will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor...

2010-12-03 07:00:00

SEATTLE, Dec. 3, 2010 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following PROVENGE® (sipuleucel-T) data presentations taking place at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida and the Society of Urologic Oncology (SUO) Annual Meeting in Bethesda, Maryland. The following data presentations will take place at the ASH Annual Meeting on Saturday, December 4, 2010, at 5:30 p.m. ET: A poster titled,...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.